Patents by Inventor Maximiliano Vasquez

Maximiliano Vasquez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized PAI-1 antibodies
    Patent number: 7771720
    Abstract: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: August 10, 2010
    Assignee: CisThera, Inc.
    Inventors: Donald E. Staunton, Maximiliano Vasquez
  • MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2
    Publication number: 20100196364
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: November 6, 2009
    Publication date: August 5, 2010
    Applicant: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • Humanized Endoglin Antibodies
    Publication number: 20100098692
    Abstract: The present application relates to compositions of humanized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the use of humanized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
    Type: Application
    Filed: September 30, 2009
    Publication date: April 22, 2010
    Applicant: TRACON PHARMACEUTICALS, INC., a Delaware Corporation
    Inventors: Charles Theuer, Maximiliano Vasquez
  • Rationally Designed, Synthetic Antibody Libraries and Uses Therefor
    Publication number: 20100056386
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system, with or without DH segments derived from other species, and are based on rational design informed by examination of publicly available databases of antibody sequences.
    Type: Application
    Filed: March 13, 2009
    Publication date: March 4, 2010
    Applicant: Adimab, Inc.
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. D. Wittrup
  • Methods of treatment of autoimmune diseases using humanized immunoglobulin reactive with B7-2
    Patent number: 7666421
    Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: February 23, 2010
    Assignee: Genetics Institute, LLC
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
  • Humanized monoclonal antibodies to hepatocyte growth factor
    Patent number: 7632926
    Abstract: The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: December 15, 2009
    Assignee: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Hangil Park, Lihong Wang, Maximiliano Vasquez
  • MONOCLONAL ANTIBODIES TO BASIC FIBROBLAST GROWTH FACTOR
    Publication number: 20090304707
    Abstract: The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: May 28, 2009
    Publication date: December 10, 2009
    Applicant: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Lihong Wang, Hangil Park, Maximiliano Vasquez
  • HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE
    Publication number: 20090238821
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Application
    Filed: February 8, 2008
    Publication date: September 24, 2009
    Applicant: ELI LILLY CORPORATION
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Rationally Designed, Synthetic Antibody Libraries and Uses Therefor
    Publication number: 20090181855
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences.
    Type: Application
    Filed: September 12, 2008
    Publication date: July 16, 2009
    Applicant: ADIMAB, INC.
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
  • Humanized PAI-1 Antibodies
    Publication number: 20090136500
    Abstract: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.
    Type: Application
    Filed: November 20, 2008
    Publication date: May 28, 2009
    Applicant: CISTHERA INCORPORATED
    Inventors: Donald E. Staunton, Maximiliano Vasquez
  • Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules
    Patent number: 7531175
    Abstract: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: May 12, 2009
    Assignee: Genetics Institute LLC
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
  • Humanized PAI-1 Antibodies
    Publication number: 20090081239
    Abstract: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.
    Type: Application
    Filed: September 5, 2008
    Publication date: March 26, 2009
    Applicant: CisThera Incorporated
    Inventors: Donald E. Staunton, Maximiliano Vasquez
  • Anti-CCR5 antibody
    Publication number: 20080107595
    Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii), two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
    Type: Application
    Filed: October 16, 2006
    Publication date: May 8, 2008
    Inventors: William C. Olson, Paul J. Maddon, Naoya Tsurushita, Paul R. Hinton, Maximiliano Vasquez
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Patent number: 7365168
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: April 29, 2008
    Assignee: PDL BioPharma, Inc.
    Inventors: Paul Hinton, Naoya Tsurushita, J. Yun Tso, Maximiliano Vasquez
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Patent number: 7361740
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: April 22, 2008
    Assignee: PDL BioPharma, Inc.
    Inventors: Paul R. Hinton, Naoya Tsurushita, J. Yun Tso, Maximiliano Vasquez
  • Humanized monoclonal antibodies to hepatocyte growth factor
    Publication number: 20080019974
    Abstract: The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: March 29, 2007
    Publication date: January 24, 2008
    Applicant: Galaxy Biotech, LLC
    Inventors: Kyung Kim, Hangil Park, Lihong Wang, Maximiliano Vasquez
  • Methods of treating thrombotic diseases with von Willebrand factor specific antibodies
    Patent number: 7311913
    Abstract: Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: December 25, 2007
    Assignee: Ajinomoto Co., Inc.
    Inventors: Man Sung Co, Maximiliano Vasquez
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Patent number: 7217797
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: May 15, 2007
    Assignee: PDL Biopharma, Inc.
    Inventors: Paul R. Hinton, Naoya Tsurushita, J. Yun Tso, Maximiliano Vasquez
  • Humanized antibodies that sequester abeta peptide
    Patent number: 7195761
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13–28 of the amyloid beta peptide A?.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: March 27, 2007
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Humanized antibodies to gamma-interferon
    Patent number: 7183390
    Abstract: The invention provides humanized immunoglobulins that bind to and neutralize ?-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: February 27, 2007
    Assignee: PDL BioPharma, Inc.
    Inventors: Maximiliano Vasquez, Nicholas F. Landolfi, Naoya Tsurushita, Cary L. Queen